$2.37
0.2210.23%
At close: -
$2.27
-0.10-4.22%
After Hours: 9:25 AM EDT
Comments
Loading...
GT Biopharma Analyst Ratings and Price Targets | NASDAQ:GTBP | Benzinga
GT Biopharma Inc has a consensus price target of $6 based on the ratings of 3 analysts. The high is $11 issued by Roth MKM on December 2, 2024. The low is $2 issued by EF Hutton on August 7, 2023. The 3 most-recent analyst ratings were released by Roth MKM, HC Wainwright & Co., and EF Hutton on December 2, 2024, August 8, 2023, and August 7, 2023, respectively. With an average price target of $6 between Roth MKM, HC Wainwright & Co., and EF Hutton, there's an implied 164.32% upside for GT Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings
Analyst Ratings for GT Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/02/2024 | Buy Now | 384.58% | Roth MKM | Jonathan Aschoff32% | → $11 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 120.26% | HC Wainwright & Co. | Robert Burns42% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -11.89% | EF Hutton | Tony Butler42% | → $60 | Reiterates | Hold → Hold | Get Alert |
| 06/05/2023 | Buy Now | 120.26% | HC Wainwright & Co. | Robert Burns42% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | 120.26% | HC Wainwright & Co. | Robert Burns42% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | -11.89% | EF Hutton | Tony Butler42% | → $60 | Reiterates | Hold → Hold | Get Alert |
| 04/03/2023 | Buy Now | 120.26% | HC Wainwright & Co. | Robert Burns42% | → $150 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | -11.89% | EF Hutton | Tony Butler42% | → $60 | Reiterates | → Hold | Get Alert |
| 01/05/2023 | Buy Now | -11.89% | EF Hutton | Tony Butler42% | → $60 | Initiates | → Hold | Get Alert |
| 09/13/2022 | Buy Now | 120.26% | HC Wainwright & Co. | Robert Burns42% | $750 → $150 | Maintains | Buy | Get Alert |
FAQ
What is the target price for GT Biopharma (GTBP) stock?
The latest price target for GT Biopharma (NASDAQ:GTBP) was reported by Roth MKM on December 2, 2024. The analyst firm set a price target for $11.00 expecting GTBP to rise to within 12 months (a possible 384.58% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GT Biopharma (GTBP)?
The latest analyst rating for GT Biopharma (NASDAQ:GTBP) was provided by Roth MKM, and GT Biopharma initiated their buy rating.
When was the last upgrade for GT Biopharma (GTBP)?
There is no last upgrade for GT Biopharma
When was the last downgrade for GT Biopharma (GTBP)?
There is no last downgrade for GT Biopharma.
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on December 2, 2024 so you should expect the next rating to be made available sometime around December 2, 2025.
Is the Analyst Rating GT Biopharma (GTBP) correct?
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a initiated with a price target of $0.00 to $11.00. The current price GT Biopharma (GTBP) is trading at is $2.27, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.